Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma

被引:16
|
作者
Moon, Seung Hwan [1 ,2 ]
Lee, Ah Young [1 ,2 ]
Kim, Won-Seog [3 ]
Kim, Seok Jin [3 ]
Cho, Young Seok [2 ]
Choe, Yearn Seong [1 ,2 ]
Kim, Byung-Tae [1 ,2 ]
Lee, Kyung-Han [1 ,2 ]
机构
[1] Sungkyunkwan Univ, Dept Nucl Med, 50 Ilwon Dong, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, 50 Ilwon Dong, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
关键词
Angioimmunoblastic T-cell lymphoma; 18F-FDG; PET/CT; prognosis; POSITRON-EMISSION-TOMOGRAPHY; F-18-FDG PET/CT; SUVMAX REDUCTION; PROGNOSTIC VALUE; NASAL TYPE; CRITERIA; GOELAMS; PROJECT; SCANS;
D O I
10.1080/10428194.2016.1236380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Subjects were 45 patients with angioimmunoblastic T-cell lymphoma (AITL) who underwent 2-[F-18]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) at baseline and interim after 2-4 cycles. Predictors of progression-free survival (PFS) and overall survival (OS) were assessed. Positive interim PET/CT (Deauville score >= 3) was a significant independent predictor of poor PFS (Hazard ratio, 4.42; p=.028), and showed marginal significance to predict OS (p=.065). Less than 60% decrease in the average change of maximum standardized uptake value normalized by lean body mass (SULmax) also was a significant independent predictor of poor PFS (Hazard ratio, 12.96; p=.001) and poor OS (Hazard ratio, 24.11; p=.006). Interim PET/CT has a significant prognostic value for predicting PFS and OS in patients with AITL. Deauville score and percent decrease of SULmax have the potential to be useful parameter in classifying patients into good and poor responders.
引用
收藏
页码:1341 / 1348
页数:8
相关论文
共 50 条
  • [21] Predicting the efficiency of chidamide in patients with angioimmunoblastic T-cell lymphoma using machine learning algorithm
    Zhang, Chunlan
    Xu, Juan
    Gu, Mingyu
    Tang, Yun
    Tang, Wenjiao
    Wang, Jie
    Liu, Qinyu
    Yang, Yunfan
    Zhong, Xushu
    Xu, Caigang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] PET in T-Cell Lymphoma
    Zinzani, Pier Luigi
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (04) : 241 - 244
  • [23] PET in T-Cell Lymphoma
    Pier Luigi Zinzani
    Current Hematologic Malignancy Reports, 2011, 6 : 241 - 244
  • [24] Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients
    Rossi, Cedric
    Kanoun, Salim
    Berriolo-Riedinger, Alina
    Dygai-Cochet, Inna
    Humbert, Olivier
    Legouge, Caroline
    Chretien, Marie Lorraine
    Bastie, Jean-Noel
    Brunotte, Francois
    Casasnovas, Rene-Olivier
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (04) : 569 - 573
  • [25] The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma
    Avigdor, Abraham
    Sirotkin, Tsvi
    Kedmi, Meirav
    Ribakovsy, Elena
    Berkowicz, Miriam
    Davidovitz, Yaron
    Kneller, Abraham
    Merkel, Drorit
    Volchek, Yulia
    Davidson, Tima
    Goshen, Elinor
    Apter, Sara
    Shimoni, Avichai
    Ben-Bassat, Isaac
    Nagler, Arnon
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1297 - 1304
  • [26] Interim FDG-PET/CT for Response Assessment of Lymphoma
    Zeman, Merissa N.
    Akin, Esma A.
    Merryman, Reid W.
    Jacene, Heather A.
    SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (03) : 371 - 388
  • [27] Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial
    Schmitz, Christine
    Rekowski, Jan
    Mueller, Stefan P.
    Hertenstein, Bernd
    Franzius, Christiane
    Ganser, Arnold
    Bengel, Frank M.
    Kroschinsky, Frank
    Kotzerke, Joerg
    La Rosee, Paul
    Freesmeyer, Martin
    Hoeffkes, Heinz-Gert
    Hertel, Andreas
    Behringer, Dirk
    Mesters, Rolf
    Weckesser, Matthias
    Mahlmann, Stefan
    Haberkorn, Uwe
    Martens, Uwe
    Prange-Krex, Gabriele
    Brenner, Winfried
    Giagounidis, Aristoteles
    Moeller, Regina
    Runde, Volker
    Sandmann, Matthias
    Hautzel, Hubertus
    Wilop, Stefan
    Krohn, Thomas
    Duerk, Heinz
    Heike, Michael
    Alashkar, Ferras
    Brinkmann, Marcus
    Trenn, Guido
    Wacker, Dietmar
    Kreisel-Buestgens, Christiane
    Bernhard, Helga
    Heil, Gerhard
    Larisch, Rolf
    Kurch, Lars
    Joeckel, Karl-Heinz
    Hoelzer, Dieter
    Klapper, Wolfram
    Boellaard, Ronald
    Duehrsen, Ulrich
    Huettmann, Andreas
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 244 - 256
  • [28] Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
    Chang, Yu
    Fu, Xiaorui
    Sun, Zhenchang
    Xie, Xinli
    Wang, Ruihua
    Li, Zhaoming
    Zhang, Xudong
    Sheng, Guangyao
    Zhang, Mingzhi
    SCIENTIFIC REPORTS, 2017, 7
  • [29] Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma
    Gurion, Ronit
    Bernstine, Hanna
    Domachevsky, Liran
    Michelson, Carmela
    Raanani, Pia
    Vidal, Liat
    Shochat, Tzippy
    Gafter-Gvili, Anat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10) : 687 - 691
  • [30] The value of routine bone marrow examination in patients with extranodal NK/T-cell lymphoma staged with PET/CT
    Yang, Yong
    Wang, Ji-Jin
    Zhao, Rui-Zhi
    Huang, Cheng
    Shi, Gui-Qing
    Zheng, Hao
    Tang, Tian-Lan
    Liao, Si-Qin
    Chen, Jin-Hua
    Shen, Jian-Zhen
    Liu, Ting-Bo
    Xu, Ben-Hua
    Zhang, Yu-Jing
    CANCER, 2022, 128 (22) : 3943 - 3950